Eberlein U[au] - Search Results

Year	Number of Results
1989	3
1990	2
1991	1
1993	1
2006	1
2011	1
2012	1
2013	1
2014	2
2015	6
2016	5
2017	4
2018	5
2019	1
2020	3
2021	3

1

The Relevance of Dosimetry in Precision Medicine.

Lassmann M, Eberlein U. Lassmann M, et al. Among authors: eberlein u. J Nucl Med. 2018 Oct;59(10):1494-1499. doi: 10.2967/jnumed.117.206649. Epub 2018 Jul 12. J Nucl Med. 2018. PMID: 30002109 Free article. Review.

2

Dosimetry of [⁶⁸Ga]-labeled compounds.

Eberlein U, Lassmann M. Eberlein U, et al. Appl Radiat Isot. 2013 Jun;76:70-4. doi: 10.1016/j.apradiso.2012.06.033. Epub 2012 Jul 20. Appl Radiat Isot. 2013. PMID: 22884623 Review.

3

Radiation Dosimetry Aspects of (177)Lu.

Lassmann M, Eberlein U. Lassmann M, et al. Among authors: eberlein u. Curr Radiopharm. 2015;8(2):139-44. doi: 10.2174/1874471008666150313104212. Curr Radiopharm. 2015. PMID: 25771372 Review.

4

Multicentre Trials on Standardised Quantitative Imaging and Dosimetry for Radionuclide Therapies.

Lassmann M, Eberlein U, Tran-Gia J. Lassmann M, et al. Among authors: eberlein u. Clin Oncol (R Coll Radiol). 2021 Feb;33(2):125-130. doi: 10.1016/j.clon.2020.11.008. Epub 2020 Dec 1. Clin Oncol (R Coll Radiol). 2021. PMID: 33277151

5

Individualized Dosimetry for Theranostics: Necessary, Nice to Have, or Counterproductive?

Eberlein U, Cremonesi M, Lassmann M. Eberlein U, et al. J Nucl Med. 2017 Sep;58(Suppl 2):97S-103S. doi: 10.2967/jnumed.116.186841. J Nucl Med. 2017. PMID: 28864620 Free article. Review.

6

DNA damage in blood leucocytes of prostate cancer patients during therapy with ¹⁷⁷Lu-PSMA.

Schumann S, Scherthan H, Lapa C, Serfling S, Muhtadi R, Lassmann M, Eberlein U. Schumann S, et al. Among authors: eberlein u. Eur J Nucl Med Mol Imaging. 2019 Jul;46(8):1723-1732. doi: 10.1007/s00259-019-04317-4. Epub 2019 Apr 27. Eur J Nucl Med Mol Imaging. 2019. PMID: 31028426 Free PMC article.

7

DNA Damage in Blood Leukocytes of Prostate Cancer Patients Undergoing PET/CT Examinations with [⁶⁸Ga]Ga-PSMA I&T.

Schumann S, Scherthan H, Frank T, Lapa C, Müller J, Seifert S, Lassmann M, Eberlein U. Schumann S, et al. Among authors: eberlein u. Cancers (Basel). 2020 Feb 7;12(2):388. doi: 10.3390/cancers12020388. Cancers (Basel). 2020. PMID: 32046191 Free PMC article.

8

Targeted alpha-particle therapy: imaging, dosimetry, and radiation protection.

Lassmann M, Eberlein U. Lassmann M, et al. Among authors: eberlein u. Ann ICRP. 2018 Oct;47(3-4):187-195. doi: 10.1177/0146645318756253. Epub 2018 Apr 17. Ann ICRP. 2018. PMID: 29664326

9

Setting up a quantitative SPECT imaging network for a European multi-centre dosimetry study of radioiodine treatment for thyroid cancer as part of the MEDIRAD project.

Taprogge J, Leek F, Schurrat T, Tran-Gia J, Vallot D, Bardiès M, Eberlein U, Lassmann M, Schlögl S, Vergara Gil A; MEDIRAD WP3 Investigator Team, Flux GD. Taprogge J, et al. Among authors: eberlein u. EJNMMI Phys. 2020 Oct 8;7(1):61. doi: 10.1186/s40658-020-00332-9. EJNMMI Phys. 2020. PMID: 33030702 Free PMC article.

10

Standardization of administered activities in paediatric nuclear medicine: the EANM perspective.

Lassmann M, Eberlein U, Lopci E, Chiti A. Lassmann M, et al. Among authors: eberlein u. Eur J Nucl Med Mol Imaging. 2016 Dec;43(13):2275-2278. doi: 10.1007/s00259-016-3474-6. Epub 2016 Aug 6. Eur J Nucl Med Mol Imaging. 2016. PMID: 27497694 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results